When to call your provider Within 24-48 hours: Positional headache not improving after 7 days of structured hydration Headache interfering with work or daily activities more than 3 days per week New headache pattern after several months on a stable dose Headache requiring daily analgesic use Same day: Headache with visual changes (blurring, double vision, blind spots) Headache with persistent vomiting Headache with confusion or difficulty concentrating beyond what's normal for you Headache that wakes you from sleep repeatedly Emergency care: Sudden severe headache reaching peak intensity within 1 minute Headache with fever and stiff neck Headache with weakness, numbness, or difficulty speaking Headache with seizure Headache after head trauma "Worst headache of my life" The threshold for imaging in GLP-1 patients with headaches is lower than in the general population because of rare but documented cases of idiopathic intracranial hypertension associated with rapid weight loss

Funding Open access funding provided by Technische Universitt Mnchen
by late 2026, though the exact date depends on FDA action
Originally developed by Novo Nordisk in the late 1990s, ipamorelin represents one of the most selective growth hormone-releasing peptides (GHRPs) available, demonstrating minimal activation of secondary hormone pathways compared to other compounds in its class
The comparison between semaglutide, tirzepatide, and retatrutide shows that each successive generation of multi-receptor agonist delivers greater weight loss outcomes
A volume of 1.2 mL of 20% TCA solution was added and samples were chilled on ice for 15 min